Experimental drug shows encouraging results in treating most common form of lung cancer
Based on this data, a Phase 2/3 trial comparing two different doses of MK-3475 to standard chemotherapy for lung cancer has begun enrolling patients. Some cancer cells can evade detection by the immune system by expressing a protein called PD-L1, which …